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Abstract (199/ 200) 
People with psychosis have high prevalence of low vitamin D levels but the 
correlates and relevance of this deficiency are unclear.  A systematic search of major 
databases from inception to 03/2016 was undertaken investigating correlates of 
vitamin D in people with psychosis. Data was summarised with a best evidence 
synthesis. Across 23 included studies (n=1,770 psychosis, n= 8,171 controls) a mean 
difference in vitamin D levels between both groups of -11.14 ng/ml 0.59 was found. 
53 unique correlations between vitamin D and outcomes in people with psychosis 
were identified.  The evidence base was broadly equivocal although season of blood 
sampling (67% of studies found a positive correlation with warmer seasons) and 
parathyroid hormone (100% of studies found a negative correlation) were associated 
with vitamin D levels. The most commonly non-correlated variables were: BMI (83% 
found no correlation), age (73%), gender (86%), smoking (100%), duration of illness 
(100%) and general assessment of functioning score (100%). In conclusion, whilst 
many unique correlates have been investigated, there is weak and inconclusive 
evidence regarding the consistency and meaning of the correlates of vitamin D levels 
in people with psychosis.  Future longitudinal studies should consider the correlates 
of vitamin D in people with psychosis. 
 
Key words: Schizophrenia; Psychosis; vitamin D; hypovitaminosis D; 25-hydroxyvitamin 
D; 25-OHD 
1. Introduction 
Psychotic disorders are one of the largest contributers to the global burden of disease 
(Whiteford et al., 2013). The prevalence of psychotic disorders varies among different 
geographical locations, with increased rates in cold climates and high latitudes (Kinney et al., 
2009). Furthermore, prevalence increases in individuals born in Winter/Spring months 
compared to Summer/Autumn babies (Kinney et al., 2009; Saha et al., 2005). These 
ecological findings suggest sun exposure and therefore vitamin D is a risk factor for 
psychotic disorders. These findings are consistent with the increased rates of psychotic 
disorders observed in Black ethnic migrant groups (Cantor-Graae and Selten, 2005; 
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Dealberto, 2010) partially due to darker skin pigments being less able to absorb Ultraviolet B 
(UVB) radiation, higher rates in urban compared with rural areas and the high ratio of 
patients diagnosed being born in winter months (McGrath, 1999; McGrath et al., 2004).  
The association between vitamin D and psychotic disorders has become of increasing 
interest. Recently vitamin D deficiency was demonstrated in two meta-analyses in patients 
with psychotic disorders versus controls (Belvederi Murri et al., 2013; Valipour, Saneei & 
Esmaillzadeh, 2014). Low vitamin D levels have been reported in established (Lally et al., 
2016) and first episode psychosis (FEP) (Crews et al., 2013). However, to what extent 
hypovitaminosis D is related to disease mechanisms or influences health outcomes among 
this population is unknown. One study examining the effects of supplementation with 
vitamin D in the first year of life found that an intake of 2000 international units (IU) or 
more per day was associated with a significant reduced risk of developing a psychotic 
disorder in males (RR = .23, CI = .06-.95) (McGrath et al., 2004). Furthermore, low vitamin D 
prenatally could impact on fetal neural development, increasing one’s risk of developing a 
psychotic disorder later in life (Eyles et al., 2013). These findings suggest an association 
between vitamin D and psychotic disorders. 
In the general population, vitamin D deficiency has been linked to increased risk of 
Cardiovascular Disease (CVD) and related disorders such as stroke, hypertension and heart 
failure (Liu et al., 2012). Evidence suggests that low vitamin D is associated with some 
physical health factors such as high body mass index (BMI) (Vimaleswaran et al., 2013), 
larger waist circumference (Lally et al., 2016) and increased rates of smoking (Cutillas-Marco 
et al., 2012), all risk factors for CVD. Furthermore, hypovitaminosis D is a risk factor for 
osteoporosis in certain age groups (van Schoor et al., 2008) and type 2 diabetes mellitus in 
women (Lindqvist et al., 2010). Emerging evidence suggests that hypovitaminosis D may be 
a risk-modifying factor for psychotic disorders as well as for other chronic illnesses including, 
type 1 diabetes, multiple sclerosis, rickets, heart disease, osteomalacia and cancer 
(Kaludjerovic & Vieth, 2010). More recently in human studies, vitamin D deficiency has been 
linked to dysfunction of the hippocampus, a region thought to be involved in the 
pathogenesis of psychotic disorders, and a positive correlation between vitamin D and 
regional grey matter volume (Shivakumar et al., 2015).  
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Previous systematic reviews have concentrated on comparing the mean difference in 
vitamin D levels between psychotic disorders and healthy controls (Belvederi Murri, et al., 
2013; Valipour et al., 2014). Whilst previous reviews have confirmed people with psychosis 
experience low levels of vitamin D, no systematic review to our knowledge has considered 
the correlates of vitamin D deficiency in this patient group. Therefore, a review 
systematically examining the correlates of vitamin D in people with psychosis is needed in 
order to understand the association between vitamin D level and other examined variables.  
The aims of this review was to provide an update on vitamin D levels in psychotic disorders 
and systematically examine the correlates of vitamin D in people with psychosis.  
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1. Methods 
This systematic review was conducted in line with the PRISMA statement (Moher, Liberati, 
Tetzlaff, & Altman, 2009). 
 
2.1 Inclusion criteria 
The Inclusion criteria for this systematic review were studies that; (1) included participants 
with psychotic disorders (schizophrenia, schizoaffective disorder or psychotic disorder NOS), 
formally diagnosed according to established criteria (e.g., DSM-IV, (APA, 2000) or ICD-10, 
(World Health Organisation, 1992)). (2) Included a measurement of vitamin D levels (25-
hydroxyvitamin D (25-OHD)) within a psychotic disorder population. (3) are published in an 
international peer review journal in the English language. 
 
2.2 Exclusion criteria 
The exclusion criteria for this review were studies that; (1) did not differentiate between 
different diagnoses when presenting data, i.e. put all mental disorders together as one group. 
(2) Did not report vitamin D mean values. (3) Conference abstracts. 
 
2.3 Information sources and searches 
The study author searched; MEDLINE, PsycINFO and EMBASE from database inception until 
4th March 2016, using the key words ‘Vitamin D’ AND ‘Schizophrenia’ OR ‘schiz*’ OR 
‘psychosis’.  In addition, reference lists of two previous reviews of vitamin D and 
Schizophrenia or psychosis were screened to identify additional studies (Belvederi Murri et 
al., 2013; Valipour, Saneei, & Esmaillzadeh, 2014).  
 
2.4 Study selection 
After removal of duplicates, author JA screened the titles and abstracts of all potentially 
eligible articles. These were then double-checked by an independent researcher (BS) to 
confirm that the eligibility criteria were adhered to. After applying the eligibility criteria, a list 
of full text articles was developed through consensus. The full texts of included articles were 
then considered and a final list of included articles was reached through consensus.  
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2.5 Outcomes 
The outcomes of interest were the mean and standard deviation (SD) of vitamin D levels 
(ng/ml) in people with psychotic disorders compared to healthy controls. If vitamin D levels 
were measured using alternative units of measurement (e.g. nmol/L, mcg/L) they were 
converted into nanograms per millilitre (ng/ml). Additional outcomes were any correlate of 
vitamin D among people with psychosis, as described in the primary study data. 
 
2.6 Data Extraction 
Author JA extracted the data using Microsoft Excel, including: study setting (inpatients, 
outpatients, community or mixed), geographical country and region, study design, first 
episode psychosis, mental illness type (schizophrenia, psychosis or other[specified]), duration 
of illness, sex, age, proportion with vitamin D deficiency, deficiency level cut-off , plasma or 
serum vitamin D samples, BMI, tobacco smoking, proportion prescribed antipsychotic 
medication and finally, the mean and SD for vitamin D in people with and without psychosis 
was collected.   
 
2.7 Correlate Outcomes 
Information on all reported significant and non-significant correlates of vitamin D levels in 
psychotic disorders were collated (as defined by primary author’s papers). To assess the effect 
and direction of the relationship between vitamin D and other variables within psychosis we 
sought to standardise the statements about statistical significance in line with guidance from 
the Canadian Agency for Drugs and Technology in Health ( 
https://www.cadth.ca/interventions-directed-professionals, CADTH, 2011). For the purpose 
of this study the categories were defined as the following: 
 0% of studies found a significant association = no evidence for an association. 
 1-33% of studies found a significant association = largely no evidence for an 
association. 
 34-66% of studies found a significant association = mixed evidence for an association. 
 67% + of studies found a significant association = good to strong evidence of an 
association. 
This method was used for all variables measured in 3 different studies.  
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2.8 Quality of included studies 
Methodological quality of the included studies, looking at correlates of vitamin D, was 
assessed using the Newcastle-Ottawa Scale (NOS) (NOS; (Wells, G., Shea., B., O’Connell, D., 
Peterson, J., Welch, V., Loscos, M, et al.,)). The scale provides an assessment of the quality of 
nonrandomized studies and its content validity and inter-rated reliability have been 
established (Wells et al.). The scale consists of three broad categories: (1) The selection of 
study participants. (2) The comparability of the groups. (3) Outcomes. Each study is rated on 
9 items with a possible overall score of up to 9 points with a higher score indicating a better 
methodological quality study.  
 
2.9 Data Synthesis 
The review is presented in a best evidence synthesis. 
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2. Results 
The initial search yielded 867 hits. After the removal of duplicates 638 abstracts and titles 
were screened. At the full text review stage 69 articles were considered and 46 were 
subsequently excluded (see Figure 1). Overall, 23 unique studies were included in the 
systematic review.   Full details of the included studies are summarised in Table 1. 
INSERT FIGURE 1 HERE (PRISMA) 
 
Across the 23 unique studies there were 1,770 individuals with a Psychotic disorder (mean 
age 42.76±12.37 years, 52.72% male (range 0-100%) with mean illness duration of 
11.34±11.31 years). Two unique studies looked at First Episode Psychosis and only one study 
included longitudinal vitamin D results. Overall, the mean BMI among participants was 
27.5±3.08 and 42.62%±13.31 smoked. There were 8,171 healthy control participants (mean 
age 40.29±12.13 years, 47.61% male (range 0-100%) with a BMI of 25.95±1.69, of whom 
22.83%±5.13 smoked (smoking only reported in 3 studies).  
Vitamin D was obtained in plasma and serum samples across six and 17 comparisons, 
respectively and vitamin D levels were standardised to ng/ml to allow for cross comparison. 
Mean vitamin D levels in the patient population were 18.62±8.35 ng/ml and in the healthy 
control population 29.76±12.13 ng/ml, a mean difference of 11.14 ng/ml (p<.0001, d=.96). 
Vitamin D deficiency rates ranged from 0-100% with a mean of 63.24%, depending on the 
level considered deficient which ranges from 10-40 ng/ml. In studies categorising the 
deficiency levels conservatively at 10ng/ml the deficiency rates in the patient populations 
were 0% and 48.8% (Bergemann, Parzer, Mundt, & Auler, 2008; Lally et al., 2016, 
respectively). 
There are more comparisons than included studies as a number of studies reported vitamin 
D levels stratified by diagnosis, length of stay or by first or multiple episodes of psychosis. 
Overall six, six and eleven comparisons were available in Asia, North America and Europe 
respectively. For a detailed summary of included studies see Table 1. 
 
INSERT TABLE 1 HERE 
 
 9 
3.1 Quality of included studies 
The quality of the included studies was assessed using the NOS 9-point scale, with a higher 
score indicating a better quality methodological study. The average quality score across the 
included 23 studies was 4.941.34 and ranged from 3 to 7 points out of the possible 9, a 
summary of the scores is presented in Table 2. 
INSERT TABLE 2 HERE 
3.2 Correlates of vitamin D among people with psychosis 
Full details of the correlates are summarised in tables 2 and 3.  In total, 16 studies out of the 
23 included within the review report a total of 53 different correlations. Correlates with mixed 
or significant findings were: Season of blood sampling (4 significant findings, 67%) suggesting 
good to strong evidence of a positive correlation with summer months (more daylight 
exposure); ethnicity (2 sig, 50%) suggesting mixed evidence for a correlation; Parathyroid 
Hormone (PTH) Level (3 sig, 100%) suggesting good to strong evidence of a negative 
correlation. The top five most reported correlations all included one or more contradicting 
results, the only correlations reported more than twice which have 100% agreement are 
smoking, duration of illness, GAF score and PTH level.   
3. Discussion 
The results from this systematic review confirm earlier meta-analyses demonstrating that 
patients with psychotic disorders have significantly lower mean levels of vitamin D compared 
to healthy controls. Furthermore, this patient group demonstrated a mean prevalence of 
vitamin D deficiency of 63.24% across the included studies. This supports previous reviews 
findings of general hypovitaminosis D in this patient population with one review findings 
59.14% and the other 65.3% (Belvederi Murri et al., 2013; Valipour et al., 2014, respectively) 
and suggests that on average over half of psychotic patients are deficient of vitamin D at any 
one time. This is in line with research in other areas suggesting that low vitamin D is also 
common in other mental health disorders such as depression and anorexia (Anglin et al., 
2013; Veronese et al., 2015, respectively). 
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The results of our comprehensive review considering the correlates of vitamin D among 
people with psychosis found that the evidence base is equivocal. However, there is evidence 
to suggest that vitamin D among people with psychosis is correlated with the season of blood 
sampling (Belzeaux et al., 2015; Berg et al., 2010; Crews et al., 2013; Grønli et al., 2014; Lally 
et al., 2016; Zhu et al., 2015) and parathyroid hormone levels (Bergemann et al., 2008; Rey-
Sánchez et al., 2009; Schneider et al., 2000), the latter being negatively correlated to vitamin 
D. What this review highlights are a multitude of variables that have been found to not 
significantly correlate with vitamin D within the patient population including but not limited 
to: BMI, age, gender, smoking, duration of illness and GAF score.  
Previous meta-analyses have focused on the mean vitamin D difference between a patient 
group and a control comparison. The first meta-analysis finding a medium effect size for lower 
vitamin D in psychotic disorders versus healthy controls (Belvederi Murri, et al., 2013). 
However, this study only included seven studies in their final report due to restrictive 
inclusion criteria and did not consider any correlational analysis. A more recent review 
included more studies and found similar results however again it did not include any 
correlational analysis (Valipour et al., 2014). Moreover, the review found significantly lower 
levels of vitamin D in case-control studies though not in cross-sectional studies. This 
systematic review goes further to include correlational analysis as an attempt to establish the 
consistency of correlates across the included studies and not the magnitude of effect. 
The season of blood sampling was found across 4 included studies to be associated with 
vitamin D levels in psychotic disorders (Berg et al., 2010; Grønli et al., 2014; Lally et al., 2016; 
Zhu et al., 2015). This is perhaps not surprising since UVB irradiation intensity varies over the 
year and it is known that in healthy populations vitamin D levels change with UVB intensity. 
In one healthy sample participants were 55% deficient during January to March but the same 
sample was only 11% deficient between July and September, ( p<.001) (Klingberg et al., 2015). 
This highlights the importance to control for the season of blood sampling when comparing 
vitamin D levels across groups. Within the same sample group, it was found that there was a 
negative correlation between BMI and vitamin D. This was not replicated in the current 
systematic review with only two out of 12 studies finding this association in psychotic disorder 
patients.  
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Parathyroid hormone was the only correlation with unanimous agreement among the 
included studies with a negative correlation to vitamin D in this patient population with three 
studies finding the same significant correlation. This relationship is expected as PTH increases 
the activity of enzymes which covert 25-hydroxycholecalciferol 25(OH)D, inactive vitamin D, 
into an active form of vitamin D (1,25(OH)2 D) in the kidney (Nussey and Whitehead, 2001). 
Therefore, with increasing PTH levels we would expect to see decreased 25(OH)D levels, the 
vitamin D level examined in the included studies. 
There is insufficient evidence identified from this systematic review to support the hypothesis 
that vitamin D might mediate cardiovascular disease risk factors in psychosis. There is 
evidence to suggest that BMI does not correlate with vitamin D levels in people with 
psychosis, with only two out of 12 studies finding a negative correlational relationship. 
Hypertension was only measured in two included studies, with one finding a significant 
negative correlation with vitamin D (Lally et al., 2016) and the other finding no significant 
effects (McCue et al., 2012). Finally, only one included study examined waist circumference 
finding a significant negative correlation with vitamin D (Lally et al., 2016). This highlights that 
the relationship between waist circumference, hypertension and vitamin D is understudied 
and this should be a priority for future research since cardiovascular disease is one of the 
leading causes for premature mortality in psychosis (Lawrence et al., 2013). Thus, the 
relationship between vitamin D and cardiovascular outcomes in people with psychosis are not 
clear.  
Whilst the results of the review are novel, some considerations should be noted. Interestingly, 
only one included study used a longitudinal design (Thakurathi et al., 2013), which is another 
key limitation in the current evidence base. The only other identified longitudinal study 
combined many mental disorders, and not just psychotic disorders, to create a patient group 
(Abdullah et al., 2012). This made the longitudinal findings difficult to generalise to psychotic 
disorders. Most of the included studies used a cross-sectional design, this only allowed us to 
examine the role of vitamin D in psychotic disorders at one time point, and no inference on 
the directionality of the association between vitamin D and psychotic disorders can be made. 
Future studies with longitudinal design are required to enable a greater understanding of 
causal inference(Levin, 2006).  
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Second, there was a vast amount of heterogeneity of the variables used, the variation of 
thresholds set and the multiple definitions of each variable. Third, there was limited data on 
many of the variables in the review. In particular, there was limited data on psychotropic 
medication and vitamin D and clinical outcomes. Future studies need to consider using 
variables that are consistent with variables from past literature in order to strengthen known 
or unknown associations. 
4.1 Conclusion 
To the best of the author’s knowledge, this review is the first to systematically review 
correlates of vitamin D and highlight the gaps in the current literature. Only the season of 
blood sampling and parathyroid hormone were consistently associated with vitamin D.  
Future research needs to consider using similar correlates to that of previous research to aid 
the understanding of associations and address the heterogeneity in the current literature, 
secondly to consider filling the gaps in the current literature including: depression, pain and 
quality of life measures and finally to improve on the current sparsity of longitudinally 
designed studies to suggest causality. 
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